Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Other Working Capital Changes (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Other Working Capital Changes for 16 consecutive years, with $24000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Working Capital Changes fell 95.95% year-over-year to $24000.0, compared with a TTM value of $1.8 million through Dec 2025, down 18.84%, and an annual FY2025 reading of $2.4 million, up 44.17% over the prior year.
  • Other Working Capital Changes was $24000.0 for Q4 2025 at Arrowhead Pharmaceuticals, up from -$20.6 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $20.3 million in Q1 2025 and bottomed at -$208.2 million in Q3 2021.
  • Average Other Working Capital Changes over 5 years is -$17.4 million, with a median of $108149.0 recorded in 2021.
  • The sharpest move saw Other Working Capital Changes plummeted 54042.81% in 2022, then soared 18880.91% in 2023.
  • Year by year, Other Working Capital Changes stood at $230000.0 in 2021, then crashed by 4677.83% to -$10.5 million in 2022, then soared by 254.91% to $16.3 million in 2023, then tumbled by 96.37% to $592000.0 in 2024, then tumbled by 95.95% to $24000.0 in 2025.
  • Business Quant data shows Other Working Capital Changes for ARWR at $24000.0 in Q4 2025, -$20.6 million in Q3 2025, and $2.0 million in Q2 2025.